[1]张运林.铝碳酸镁片联合雷贝拉唑Hp感染合并活动性消化性溃疡的安全性[J].医学信息,2020,33(24):125-127.[doi:10.3969/j.issn.1006-1959.2020.24.035]
　ZHANG Yun-lin.The Safety of Hydrotalcite Tablets Combined with Rabeprazole Hp Infection with Active Peptic Ulcer[J].Medical Information,2020,33(24):125-127.[doi:10.3969/j.issn.1006-1959.2020.24.035]
点击复制

铝碳酸镁片联合雷贝拉唑Hp感染合并活动性消化性溃疡的安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年24期
页码:
125-127
栏目:
临床研究
出版日期:
2020-12-15

文章信息/Info

Title:
The Safety of Hydrotalcite Tablets Combined with Rabeprazole Hp Infection with Active Peptic Ulcer
文章编号:
1006-1959（2020）24-0125-03
作者:
张运林
万载诚济医院内科，江西 万载 336100
Author(s):
ZHANG Yun-lin
Department of Internal Medicine,Wanzai Chengji Hospital,Wanzai 336100,Jiangxi,China
关键词:
铝碳酸镁片; 雷贝拉唑; 幽门螺杆菌; 活动性消化性溃疡
Keywords:
Hydrotalcite tablets; Rabeprazole; Helicobacter pylori; Active peptic ulcer
分类号:
R573.1
DOI:
10.3969/j.issn.1006-1959.2020.24.035
文献标志码:
A
摘要:
目的 观察铝碳酸镁片联合雷贝拉唑治疗幽门螺杆菌（Hp）感染合并活动性消化性溃疡临床疗效，评估其安全性。方法 选取2018年11月~2020年11月在我院接受治疗的106例Hp感染合并活动性消化性溃疡患者作为研究对象，采用随机数字表法分为对照组和观察组，各53例。对照组采用雷贝拉唑治疗，观察组在对照组基础上加用铝碳酸镁片治疗，比较两组临床治疗效果、Hp转阴率、临床症状评分、胃功能和炎症指标以及不良反应发生情况。结果 观察组治疗总有效率为94.33%，高于对照组的81.13%，差异有统计学意义（P＜0.05）；观察组Hp转阴率为96.22%，高于对照组的83.01%，差异有统计学意义（P＜0.05）；观察组泛酸、腹痛、嗳气、腹胀各症状评分均低于对照组，差异有统计学意义（P＜0.05）；治疗后两组胃泌素、CRP水平均低于治疗前，IL-2高于治疗前，且观察组胃泌素、CRP均低于对照组，IL-2高于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 铝碳酸镁片联合雷贝拉唑治疗Hp感染合并活动性消化性溃疡效果确切，可提高治疗效果和Hp转阴率，减轻患者症状，改善胃功能指标，促进炎症因子吸收，降低炎症因子水平，且不良反应少，应用安全性良好。
Abstract:
Objective To observe the clinical efficacy of hydrotalcite tablets combined with rabeprazole in the treatment of Helicobacter pylori (Hp) infection with active peptic ulcer, and to evaluate its safety.Methods A total of 106 patients with Hp infection and active peptic ulcer who were treated in our hospital from November 2018 to November 2020 were selected as the research objects. They were divided into control group and observation group by random number table, with 53 cases in each group. The control group was treated with rabeprazole, and the observation group was treated with hydrotalcite tablets on the basis of the control group. The clinical treatment effect, Hp negative rate, clinical symptom score, gastric function and inflammation indicators and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.33%, which was higher than 81.13% in the control group,the difference was statistically significant (P<0.05); the Hp conversion rate in the observation group was 96.22%, which was higher than 83.01% in the control group,the difference was statistically significant (P<0.05); the scores of pantothenic acid, abdominal pain, belching, and abdominal distension in the observation group were lower than those in the control group,the difference was statistically significant (P<0.05);After treatment, the levels of gastrin and CRP in the two groups were lower than before treatment, and IL-2 was higher than before treatment. Gastrin and CRP in the observation group were lower than those in the control group, and IL-2 was higher than the control group,the difference was statistically significant(P<0.05); There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Hydrotalcite tablets combined with rabeprazole is effective in treating Hp infection complicated with active peptic ulcer. It can improve the treatment effect and Hp negative rate, reduce patient symptoms, improve gastric function indexes, promote the absorption of inflammatory factors, and reduce the level of inflammatory factors and there are few adverse reactions and good application safety.

参考文献/References:

[1]熊吉军,杨静.内镜下黏膜注射联合金属钛夹与两者单用治疗溃疡病出血的临床对比研究[J].胃肠病和肝病学杂志,2014,23(6):704-707. [2]单小红.质子泵抑制剂的应用及其影响因素[J].临床合理用药杂志,2014,7(33):93-94． [3]李晓.消化性溃疡合并上消化道出血的影响因素分析[J].临床合理用药杂志,2014,7(4):12-14． [4]孙伟峰,曾杨,陈泽华,等.铝镁加混悬液联合表皮生长因子保留灌肠治疗放射性直肠炎的疗效观察[J].结直肠肛门外科,2015,21(1):47-49． [5]孙楹.康复新液联合泮托拉唑治疗消化性溃疡的疗效及安全性[J].临床合理用药杂志,2017(5):41-42． [6]陈鲜兰.泮托拉唑治疗消化性溃疡合并上消化道出血的临床治疗效果[J].药品评价,2017(1):645-646． [7]李秀丽.康复新液、凝血酶冻干粉与奥美拉唑联用方案治疗消化性溃疡出血的临床评价[J].中国现代药物应用,2016(22):112-113. [8]涂守东.兰索拉唑片治疗胃溃疡的临床效果体会[J].黑龙江医药,2016,29(3):493-495. [9]杨敏．消化性溃疡治疗中根除幽门螺杆菌效果观察[J].基层医学论坛,2016,17(14):1812-1813. [10]张明娣,时晓亚.雷贝拉唑联合康复新液治疗酒精性胃黏膜损伤所致胃炎急性发作、胃黏膜溃疡的疗效观察[J].中国医院用药评价与分析,2015,15(8):993-995． [11]李辛.左氧氟沙星三联疗法与阿莫西林三联疗法治疗消化性溃疡的疗效[J].山西医药杂志,2018,47(5):579-580. [12]朱延红,吴英杰,张春莉.雷贝拉唑与奥美拉唑四联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效比较[J].药物评价研究,2017,40(6):836-839． [13]宋东升,叶云,胥雄阳.埃索美拉唑四联方案治疗胃溃疡的临床疗效与患者的外周血T细胞亚群水平的关联性分析[J].现代免疫学,2018,38(1):25-30． [14]何小谷,方向明,汪勇,等.HP阳性消化性溃疡患者血清TGF-β1、ａ-防御素和IL－17表达的临床研究[J].实用临床医药杂志,2015,19(7):47-49． [15]齐秀荣,赵景成,宗湘裕.雷贝拉唑钠联合枸橼酸铋钾治疗消化性溃疡的临床疗效观察[J].医学综述,2014,20(12):2294-2295．

相似文献/References:

[1]夏 铭,张正坤,曾海龙,等.四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析[J].医学信息,2018,31(11):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
　XIA Ming,ZHANG Zheng-kun,ZENG Hai-long,et al.Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer[J].Medical Information,2018,31(24):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
[2]罗宜辉,刘代华.益生菌联合四联方案根除幽门螺杆菌的临床研究[J].医学信息,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
　LUO Yi-hui,LIU Dai-hua.Clinical Study on the Eradication of Helicobacter Pylori by Probiotics Combined with Quadruple Regimen[J].Medical Information,2018,31(24):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
[3]褚春沐.雷贝拉唑治疗进展性缺血性脑卒中的价值[J].医学信息,2022,35(14):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
　CHU Chun-mu.Value of Rabeprazole in Treatment of Progressive Ischemic Stroke[J].Medical Information,2022,35(24):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
[4]韩付金.雷贝拉唑肠溶胶囊联合铝碳酸镁咀嚼片用于难治性良性胃溃疡的疗效[J].医学信息,2020,33(20):141.[doi:10.3969/j.issn.1006-1959.2020.20.043]
　HAN Fu-jin.Efficacy of Rabeprazole Enteric-coated Capsules Combined with Hydrotalcite Chewable Tablets for Refractory Benign Gastric Ulcer[J].Medical Information,2020,33(24):141.[doi:10.3969/j.issn.1006-1959.2020.20.043]
[5]金志鑫,许 明.雷贝拉唑联合蓝芩口服液治疗慢性咽炎的效果及对患者临床症状、炎性因子和免疫功能的影响[J].医学信息,2023,36(24):91.[doi:10.3969/j.issn.1006-1959.2023.24.019]
　JIN Zhi-xin,XU Ming.Effect of Rabeprazole Combined with Lanqin Oral Solution in the Treatment of Chronic Pharyngitis and its Influence on Clinical Symptoms, Inflammatory Factors and Immune Function[J].Medical Information,2023,36(24):91.[doi:10.3969/j.issn.1006-1959.2023.24.019]

更新日期/Last Update: 1900-01-01